Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03599713 · ClinicalTrials.gov registry record · Phase 2
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
NCT03599713 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 107 participants.
The verdict
NCT03599713, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).
Interventions
- DRUG Retifanlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2019-02-25 |
| Est. Completion | 2024-06-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03599713
The ClinicalTrials.gov registry entry for NCT03599713 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Retifanlimab is the first listed.
NCT03599713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03599713 about?
NCT03599713 is a clinical study titled "A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)". The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).
What is the current status of trial NCT03599713?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2019-02-25. Estimated completion is 2024-06-28.
What interventions are being tested in trial NCT03599713?
The interventions under investigation include: Retifanlimab (DRUG).
Who is sponsoring clinical trial NCT03599713?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.